The attempted merger between leading biopharma data provider IQVIA and pharma ad specialist DeepIntent has been put on ice after continued scrutiny from the U.S. government. In 2022, IQVIA attempted ...
How little noise did IQVIA make about its recent highly significant acquisition of Throtle? The change in ownership is noted in a single sentence on the “About” page on Throtle’s website: “Throtle Inc ...
Hosted on MSN
IQVIA's SWOT analysis: data-driven leader faces headwinds in evolving healthcare market
IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...
A U.S. judge has upheld the Federal Trade Commission’s (FTC) decision to block IQVIA’s long-running attempt to buy the owner of pharma digital ad specialist DeepIntent. The long-running saga centers ...
IQVIA provides a broad range of services to biopharma customers, including outsourced R&D services in support of clinical trials. Recent spending caution and the end of COVID-related revenue have led ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life ...
Feb 6 (Reuters) - Contract research firm IQVIA Holdings (IQV.N), opens new tab beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare ...
IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback